Currently Viewing:
Currently Reading
Company Says It Will Seek FDA Approval for Video Game to Treat ADHD
December 07, 2017 – Allison Inserro
FDA Approves Long-Acting Version of Drug for Opioid Use Disorder
December 05, 2017 – Allison Inserro
First-of-a-Kind Companion Test for Cancer Gene Profiling Gets FDA Approval
December 04, 2017 – Jaime Rosenberg
Identifying Differences of Symptoms of Patients With Severe COPD in 3 Countries
December 04, 2017 – Laura Joszt
Sanofi Says Toujeo Met Objective in Head-to-Head Insulin Study
December 04, 2017 – Mary Caffrey
NCI Expands Clinical Trial Access for Patients With HIV in CITN-12 Trial
December 04, 2017 – Jaime Rosenberg
FDA Approves First Biosimilar for Treating Breast and Stomach Cancers
December 01, 2017 – Jaime Rosenberg
The Switch From Filgrastim to a Cheaper Alternative: Tbo-Filgrastim
December 01, 2017 – Jaime Rosenberg
Brain MRIs Can Identify ADHD and Distinguish Among Subtypes
November 29, 2017 – Laura Joszt

Company Says It Will Seek FDA Approval for Video Game to Treat ADHD

Allison Inserro
After reporting positive results of a lead investigational digital medicine, a company is planning to file for FDA approval of a video game to treat attention-deficit/hyperactivity disorder.
Could physicians prescribe digital medicine in the form of a video game for children and teenagers with attention-deficit/hyperactivity disorder (ADHD)? That’s what Akili Interactive, an affiliate of PureTech Health, is hoping after reporting positive results of its lead investigational digital medicine, AKL-T01.

The company said it is planning to file AKL-T01 with the FDA for approval after results of a randomized, controlled trial of 348 children and adolescents with ADHD showed a statistically significant improvement compared with an active control (P = .006). The predefined primary endpoint looked for a change in the Attention Performance Index (API), a composite score from the Test of Variables of Attention, an objective measure of sustained attention and inhibitory control.

“The objective improvements of attention observed in the study suggest that AKL-T01 addresses a key deficiency in ADHD that is not directly targeted by standard treatments,” Scott Kollins, PhD, professor of psychiatry, director of the ADHD Program at Duke University School of Medicine, and principal investigator for the study, said in a statement.

Current clinical guidelines for ADHD call for a combination of prescription medications and cognitive behavioral therapy.

AKL-T01 was found to be safe, with no serious adverse events. Subjective secondary outcome measures showed statistically significant positive improvements in both the treatment and active control groups, though there was not a statistically significant separation on those measures between groups.

“Since the active control group in this study also played an engaging video game, we are encouraged that the statistically significant group differences were driven by the therapeutically active component in AKL-T01 and not just the video game experience,” Kollins said.

The company said full results will be presented at an upcoming scientific conference and submitted for publication in a peer-reviewed journal.

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up